Catalent Expands Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities 6th September 2022
Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced a $2.2 million expansion to its clinical supply facility in Singapore. The investment will increase the site’s footprint by nearly 20% to 31,000 square feet, and allow the installation of 35 new freezers for ultra-low temperature (ULT) storage.
The expansion will also see the addition of specialized secondary packaging capabilities for ULT products, enabling the site’s services to support larger packaging campaigns, and increasing capabilities to handle biopharmaceuticals and advanced modalities, including mRNA-based vaccines, and cell and gene therapies.
“Our Singapore site serves as a strategic supply hub for the Asia-Pacific market, offering a wide range of services to customers in over 20 countries in the region,” said Roel de Nobel, Catalent’s Vice President and General Manager, APAC, Clinical Development & Supply. “As the site prepares to mark its 25-year anniversary, this is the latest in a series of investments and expansions that it has undertaken to meet the increasing and diversified demands of customers in their mission to develop life-changing medicines for both the region and the world.”
Alongside sites in China and Japan, Catalent’s site in Singapore serves the Asia-Pacific region with a wide range of clinical supply services including clinical supply management, comparator sourcing, Catalent’s FastChain® demand-led supply solution, secondary packaging, storage, and global distribution, as well as clinical returns and destruction.
NOTES FOR EDITORS
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of nearly 7,000 products annually. Catalent’s expert workforce of approximately 19,000 includes more than 2,500 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit www.catalent.com.